Agilent Technologies Inc (A): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Agilent Technologies ( A) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.6%. By the end of trading, Agilent Technologies fell $0.74 (-1.4%) to $53.11 on light volume. Throughout the day, 1,739,590 shares of Agilent Technologies exchanged hands as compared to its average daily volume of 2,683,900 shares. The stock ranged in price between $53.02-$54.13 after having opened the day at $54.11 as compared to the previous trading day's close of $53.85. Other companies within the Health Care sector that declined today were: Mast Therapeutics ( MSTX), down 38.6%, OraSure Technologies ( OSUR), down 16.6%, ERBA Diagnostics ( ERB), down 16.4% and Bacterin International Holdings ( BONE), down 15.9%.

Agilent Technologies, Inc. provides bio-analytical and electronic measurement solutions and services to the life sciences, chemical analysis, diagnostics and genomics, communications, and electronics industries worldwide. Agilent Technologies has a market cap of $17.9 billion and is part of the health services industry. The company has a P/E ratio of 18.8, above the S&P 500 P/E ratio of 17.7. Shares are up 31.5% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate Agilent Technologies a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Agilent Technologies as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Prima Biomed ( PBMD), up 38.9%, Ariad Pharmaceuticals ( ARIA), up 35.7%, ImmunoCellular Therapeutics ( IMUC), up 35.7% and IntelliPharmaCeutics International ( IPCI), up 19.0% , were all gainers within the health care sector with Vertex Pharmaceuticals ( VRTX) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Will Inflation Set Stocks' Hearts Aflutter or Be a Poison Arrow? -- Market Recon

Will Inflation Set Stocks' Hearts Aflutter or Be a Poison Arrow? -- Market Recon

7 Investment Themes You Can't Afford to Miss for 2018

7 Investment Themes You Can't Afford to Miss for 2018

DOJ Seeks to Block AT&T's Acquisition of Time Warner: LIVE MARKETS BLOG

DOJ Seeks to Block AT&T's Acquisition of Time Warner: LIVE MARKETS BLOG

Wall Street Finishes in the Green After Two Weeks of Losses

Wall Street Finishes in the Green After Two Weeks of Losses

Consumer and Industrial Stocks Push Dow Higher After Two Weeks of Losses

Consumer and Industrial Stocks Push Dow Higher After Two Weeks of Losses